Statistics from Altmetric.com
Natalizumab (NTZ; Biogen Idec, Cambridge, Massachusetts, USA) is a recombinant humanised immunoglobulin G4 monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS).1 It selectively inhibits the adhesion α4-β1 receptor on the surface of lymphocytes, monocytes, basophils and eosinophils preventing the interaction of immune cells with the integrin vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells and with structures of the extracellular matrix and hindering cells from leaving the vascular compartment of the brain.2 This mainly hinders circulating cells from leaving the vascular compartment but may also have other consequences on signalling and apoptosis.3
We report the case of a patient with NTZ-treated RRMS who developed a new type of atypical lesion on MRI, consisting of a transient and ill-defined gadolinium enhancement without a typically associated T2 or fluid-attenuated inversion recovery (FLAIR) lesion.
A patient was diagnosed with RRMS in 2004 with, on average, one relapse per 18 months. Treatment was switched from interferon-β1a (IFNβ-1a) 44 µg three times weekly to NTZ. Follow-up imaging was performed 1 year after treatment modification and demonstrated the appearance of two atypical contrast-enhancing lesions. The first lesion appeared in the right temporal white matter adjacent to the ventricular system with a …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.